A flexible dose-response modeling framework based on continuous toxicity outcomes in phase I cancer clinical trials.

Phase I cancer clinical trials, designed within a fully Bayesian framework with the utilization of continuous toxicity outcomes, offer an alternative approach to finding an optimal dose, providing unique benefits compared to trials designed based on binary toxicity outcomes.